Tissue-Engineered Bone formation In Vivo for Artificial Laminae of the Vertebral Arch Using Beta-tricalcium Phosphate Bioceramics Seeded with Mesenchymal Stem Cells.
ABSTRACT Study Design. A rabbit laminectomy model was used to evaluate the efficacy of artificial laminae of vertebral arch using bone marrow-derived mesenchymal stem cells (MSCs) transplanted in porous beta-calcium phosphates (β-TCP) bioceramics.Objective. The aim of this study was to establish artificial lamina of the vertebral arch for bone tissue engineering using β-TCP bioceramics seeded with MSCs in a rabbit model of decompressive laminectomy.Summary of Background Data. Decompressive laminectomy may induce various degrees of scar tissue and adhesion formation in the epidural space, and thus is the most common cause of failed back surgery syndrome. However, there is no effective method of bone defect treatment to control and reduce the scar tissue formation.Methods. MSCs were harvested from New Zealand rabbits (2 weeks old) by femoral bone marrow extraction. These cells were seeded into porous β-TCP bioceramics and cultivated for up to 3 weeks in the presence of osteogenic supplements. Segmental defects (20 mm × 8 mm) were created in 48 adult New Zealand rabbits that underwent laminectomy at the L5 to L6 levels. The animals were transplanted with cell media (control), β-TCP bioceramics (Group I), or MSC-loaded β-TCP bioceramics (Group II). Bone formation was evaluated after operation using scanning electron microscopy (SEM), computed tomography (CT), magnetic resonance imaging (MRI), histomorphometry, and immunohistochemistry.Results. SEM showed that MSCs filled the pores and surfaces of bioceramics in MSC-loaded β-TCP. In addition, significant increases in bone formation were observed in Group II compared with other groups. CT and MRI examination at 16 weeks showed that the artificial lamina of the vertebral arch was successfully formed. Hematoxylin-eosin and Masson's trichrome staining were used to show the artificial laminae of the vertebral arch and the degraded bioceramics. In addition, immunohistochemistry results showed that the expression of bone morphogenetic protein-2 increased significantly in Group II compared with Group I at 2,4, and 8 weeks following implantation (P < 0.05).Conclusion. β-TCP bioceramics seeded with MSCs are promising source of tissue-engineered bone for the artificial lamina of the vertebral arch.
- [Show abstract] [Hide abstract]
ABSTRACT: Human bone marrow-derived mesenchymal stem cells (MSCs) can self-renew and differentiate into osteoblasts, chondrocytes, and adipocytes. MSCs have effectively emerged as a promising tool for clinical applications, specifically in musculoskeletal diseases. This article reviews the status of preclinical animal studies, clinical trials, and the efforts of the industry in using MSCs to treat musculoskeletal diseases such as bone fractures, bone defects, focal chondral lesions, osteoarthritis, spinal diseases, and tendon injuries. We also discuss the current problems encountered and potential of using MSCs in future clinical studies.Cell Transplantation 04/2014; 23(4):505-12. · 3.57 Impact Factor